LDX
data caveat$161M—
Lumos Diagnostics
Diagnostics · Infectious disease
Point-of-care diagnostics company. FebriDx rapid test differentiates bacterial vs viral acute respiratory infections. Pediatric validation study recruiting.
Data HealthFiling4C overdue · Dec 202580dTrials1 of 1 active · stale enrollment
No cash data on fileFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
—
Runway
—Market Cap
$161M
Burn Rate
—
Shares Outstanding
923M
Pipeline Assets
1
Latest Insight(1)
14 Apr 2026substantial_holderChange in substantial holding from RYD
Changed·Ryder Capital Ltd and related entities·14.73%
3M Price
LDX.ASX$0.175-25.5% 3M
Low $0.170High $0.305
Pipeline Assets (1)
FebriDxAcute respiratory infections
ApprovedDiscovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
FebriDx
Acute respiratory infections
Capital Raises & Buybacks
1 raise
Current shares outstanding: 923M
SPP
2026-04-10spp
$2.0M
Substantial Holders (5%+ threshold)
1 noticearrow_drop_downRyder Capital Ltd and related entities
14.73%2026-04-14
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
119 competitor trialsPhase 2+ · Non-ASX
Acute Respiratory Infections119 active trials
15 Ph430 Ph311 Ph2/353 Ph210 Ph1/PHASE2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
1 paper
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
Catalysts (5)· 3 upcoming · 2 past
FebriDx US commercial scale-up
UpcomingConfirmedarrow_upwardHigh30 June 2026
FebriDx paediatric BARDA study completion
UpcomingExpectedarrow_upwardHigh30 Sept 2026
FebriDx paediatric FDA 510(k) submission
UpcomingExpectedarrow_upwardHigh31 Mar 2027
expand_more2 past catalysts
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
0/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
⚠ TIMELINE CHANGESCT.GOV · AUTO-DETECTED
These changes were automatically detected by comparing ClinicalTrials.gov records over time. A slipped date means the trial's expected completion moved later; pulled forward means it moved earlier.
Clinical Trials(3)
1 activeClinicalTrials.gov ↗
RecruitingOBSERVATIONALEnrollment stale · 195d
FebriDx
FebriDx® Pediatric Validation Study
Acute Respiratory Infections (ARIs)
2 Years – 11 Years
Primary endpoint Performance of the FebriDx® test